Clarius Group LLC Has $496,000 Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Clarius Group LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,709 shares of the pharmaceutical company’s stock after acquiring an additional 155 shares during the period. Clarius Group LLC’s holdings in Vertex Pharmaceuticals were worth $496,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. OmniStar Financial Group Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at $26,000. CX Institutional grew its holdings in shares of Vertex Pharmaceuticals by 103.8% in the 1st quarter. CX Institutional now owns 108 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 55 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at $28,000. Advisory Alpha LLC grew its holdings in shares of Vertex Pharmaceuticals by 109.9% in the 4th quarter. Advisory Alpha LLC now owns 170 shares of the pharmaceutical company’s stock valued at $39,000 after buying an additional 89 shares during the period. Finally, Americana Partners LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $37,000. 93.40% of the stock is owned by hedge funds and other institutional investors.

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 32,792 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $286.15, for a total transaction of $9,383,430.80. Following the transaction, the chairman now owns 29,252 shares in the company, valued at approximately $8,370,459.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Paul M. Silva sold 859 shares of the stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $248.72, for a total transaction of $213,650.48. Following the transaction, the senior vice president now owns 15,791 shares in the company, valued at approximately $3,927,537.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 303,424 shares of company stock worth $83,791,273. 0.70% of the stock is owned by company insiders.

Several equities research analysts recently commented on VRTX shares. Goldman Sachs Group boosted their price objective on shares of Vertex Pharmaceuticals from $290.00 to $330.00 and gave the company a “conviction-buy” rating in a research report on Thursday, July 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $275.00 price objective (up from $262.00) on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 11th. Argus boosted their price objective on shares of Vertex Pharmaceuticals from $270.00 to $320.00 and gave the company a “buy” rating in a research report on Friday, May 15th. SVB Leerink boosted their price objective on shares of Vertex Pharmaceuticals from $224.00 to $263.00 and gave the company a “market perform” rating in a research report on Thursday, April 30th. Finally, Wolfe Research started coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, March 12th. They issued an “outperform” rating and a $282.00 price objective on the stock. Nine equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average price target of $285.12.

Shares of VRTX opened at $295.92 on Thursday. Vertex Pharmaceuticals Incorporated has a 52 week low of $165.23 and a 52 week high of $306.08. The firm has a market cap of $77.54 billion, a P/E ratio of 51.29, a price-to-earnings-growth ratio of 1.44 and a beta of 0.94. The firm’s 50-day simple moving average is $282.14 and its 200 day simple moving average is $249.71. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.42 and a current ratio of 3.54.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, April 29th. The pharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.84 by $0.72. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 25.69%. The business had revenue of $1.52 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the prior year, the business earned $1.14 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 76.8% on a year-over-year basis. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 7.35 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Further Reading: Depreciation

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.